Ross Kedl, PhD

Professor of Immunology & Microbiology
University of Colorado

Ross KedlDr. Kedl received his PhD in 1997 in the Department of Laboratory Medicine and Pathology at the University of Minnesota in Minneapolis. Before joining the Faculty at the University of Colorado, Dr. Kedl was at 3M Pharmaceuticals working in their small molecule immune response modifier program. In his three years there, he spearheaded efforts at developing novel vaccine adjuvants, resulting in numerous publications and patents in the area of vaccine technology. Dr. Kedl returned to the academic sector in 2004 by joining the faculty in the Integrated Department of Immunology at the University of Colorado Health Sciences Center and National Jewish Medical Research Center where he continues to pursue the discovery and development of novel and clinically applicable vaccine technology. He is also the founder of a start-up pharmaceutical company, ImmuRx Inc., which focuses on developing therapeutic vaccines against chronic infectious diseases, such as HIV and cancer.

Biography from University of Colorado.

IDIGH Calendar

<<  <  January 2020  >  >>
 Mo  Tu  We  Th  Fr  Sa  Su 
    1  2  3  4  5
  6  7  8  9101112
13141516171819
202123242526
27283031  

Latest IDIGH Publications

  1. Kunovszki, P., Szántó, K. J., Gimesi-Országh, J., Takács, P., Borsi, A., Bálint, A., Farkas, K., Milassin, Á., Lakatos, P. L., Szamosi, T. & Molnár, T.
    (2020)
    .
    Epidemiological data and utilization patterns of anti-TNF alpha therapy in the Hungarian ulcerative colitis population between 2012-2016
    .
    Expert opinion on biological therapy
  2. Butler-Laporte, G., Cheng, M. P., McDonald, E. G. & Lee, T. C.
    (2020)
    .
    Using VRE screening tests to predict vancomycin resistance in enterococcal bacteremia
    .
    Infection control and hospital epidemiology
    ,
    p
    .
    1-5
    .
  3. Nixon, C. C., Mavigner, M., Sampey, G. C., Brooks, A. D., Spagnuolo, R. A., Irlbeck, D. M., Mattingly, C., Ho, P. T., Schoof, N., Cammon, C. G., Tharp, G. K., Kanke, M., Wang, Z., Cleary, R. A., Upadhyay, A. A., De, C., Wills, S. R., Falcinelli, S. D., Galardi, C., Walum, H., Schramm, N. J., Deutsch, J., Lifson, J. D., Fennessey, C. M., Keele, B. F., Jean, S., Maguire, S., Liao, B., Browne, E. P., Ferris, R. G., Brehm, J. H., Favre, D., Vanderford, T. H., Bosinger, S. E., Jones, C. D., Routy, J.-P., Archin, N. M., Margolis, D. M., Wahl, A., Dunham, R. M., Silvestri, G., Chahroudi, A. & Garcia, J. V.
    (2020)
    .
    Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo
    .
    Nature
  4. Deshmukh, H., Rambach, G., Sheppard, D. C., Lee, M., Hagleitner, M., Hermann, M., Würzner, R., Lass-Flörl, C. & Speth, C.
    (2020)
    .
    Galactosaminogalactan secreted from Aspergillus fumigatus and Aspergillus flavus induces platelet activation
    .
    Microbes and infection
  5. Sulis, G. & Pai, M.
    (2020)
    .
    Isoniazid-resistant tuberculosis: A problem we can no longer ignore
    .
    PLoS medicine
    ,
    vol
    .
    17
    ,
    p
    .
    e1003023
    .
More publications